Kalvista Pharma CFO Piekos sells $27,506 in shares
#KalVista Pharmaceuticals #Brian Piekos #CFO #SEC Form 4 #Stock Sale #KALV #Insider Trading #Pharmaceutical Stocks
📌 Key Takeaways
- KalVista Pharmaceuticals CFO Brian Piekos sold $27,506 worth of company shares
- The transaction involved 1,767 shares at an average price of $15.5668 per share
- The sale was officially reported on February 23, 2026 via SEC Form 4 filing
- KalVista stock has increased by 46% over the past year, currently trading at $15.77
📖 Full Retelling
Brian Piekos, Chief Financial Officer of KalVista Pharmaceuticals (NASDAQ:KALV), sold 1,767 shares of common stock on February 23, 2026, in a transaction valued at $27,506, as disclosed in a recent SEC Form 4 filing. The shares were sold at a weighted average price of $15.5668, with individual share prices ranging from $15.5253 to $15.56698. This insider transaction comes as KalVista's stock currently trades at $15.77, reflecting a 46% increase over the past year. The company, which focuses on developing innovative therapies for complement-mediated diseases, has seen its stock price appreciate despite the insider sale by one of its top executives. Such transactions by corporate insiders are closely monitored by investors as they may provide insights into executive sentiment about the company's near-term prospects, though sales can be motivated by personal financial planning rather than concerns about the company's outlook.
🏷️ Themes
Corporate Insider Trading, Pharmaceutical Industry, Stock Market Performance
📚 Related People & Topics
Chief financial officer
Person in a company or organization responsible for finances
A chief financial officer (CFO) is an officer of a company or organization who is assigned the primary responsibility for making decisions for the company for projects and its finances; i.a.: financial planning, management of financial risks, record-keeping, and financial reporting, and, increasingl...
Entity Intersection Graph
Connections for Chief financial officer:
View full profileOriginal Source
Brian Piekos, Chief Financial Officer of KalVista Pharmaceuticals NASDAQ:KALV, sold 1,767 shares of common stock on February 23, 2026, according to a recent SEC Form 4 filing. The shares were sold at a weighted average price of $15.5668, resulting in a total transaction value of $27,506. Prices ranged from $15.5253 to $15.56698 per share. The stock currently trades at $15.77, up 46% over the past year.
Read full article at source